Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kosuke Hashimoto

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
Scientific Reports|May 12, 2026
Early FMISO PET changes as exploratory predictors of immune checkpoint inhibitor response in advanced lung cancer: a pilot studyKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2019
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutationOu Yamaguchi, Kyoichi Kaira, Atsuto Mouri, et al.
Translational Lung Cancer Research|May 22, 2026
TROP2 expression as a prognostic predictor for osimertinib in patients with <i>EGFR</i>-mutant non-small cell lung cancerNaohito Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
International Journal of Clinical Oncology|December 31, 2023
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancerAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2022
Prognostic Potential of Metabolic Activity on 18 F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 BlockadeKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Scientific Reports|April 26, 2019
OVOL2 induces mesenchymal-to-epithelial transition in fibroblasts and enhances cell-state reprogramming towards epithelial lineagesKazuhide Watanabe, Ye Liu, Shuhei Noguchi, et al.
Clinical Nuclear Medicine|January 10, 2022
Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non-Small Cell Lung CancerKosuke Hashimoto, Kyoichi Kaira, Ou Yamaguchi, et al.
Thoracic Cancer|March 14, 2019
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancerTakahiro Uchida, Kyoichi Kaira, Ou Yamaguchi, et al.
Frontiers in Oncology|April 1, 2021
Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody TitersAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Thoracic Cancer|November 13, 2020
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumabOu Yamaguchi, Kyoichi Kaira, Shun Shinomiya, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Scientific Reports|May 12, 2026
Early FMISO PET changes as exploratory predictors of immune checkpoint inhibitor response in advanced lung cancer: a pilot studyKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2019
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutationOu Yamaguchi, Kyoichi Kaira, Atsuto Mouri, et al.
Translational Lung Cancer Research|May 22, 2026
TROP2 expression as a prognostic predictor for osimertinib in patients with <i>EGFR</i>-mutant non-small cell lung cancerNaohito Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
International Journal of Clinical Oncology|December 31, 2023
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancerAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2022
Prognostic Potential of Metabolic Activity on 18 F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 BlockadeKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Scientific Reports|April 26, 2019
OVOL2 induces mesenchymal-to-epithelial transition in fibroblasts and enhances cell-state reprogramming towards epithelial lineagesKazuhide Watanabe, Ye Liu, Shuhei Noguchi, et al.
Clinical Nuclear Medicine|January 10, 2022
Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non-Small Cell Lung CancerKosuke Hashimoto, Kyoichi Kaira, Ou Yamaguchi, et al.
Thoracic Cancer|March 14, 2019
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancerTakahiro Uchida, Kyoichi Kaira, Ou Yamaguchi, et al.
Frontiers in Oncology|April 1, 2021
Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody TitersAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Thoracic Cancer|November 13, 2020
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumabOu Yamaguchi, Kyoichi Kaira, Shun Shinomiya, et al.
Pageof 14